Page 3 - இன்டாஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Global Oncology Biosimilars Market Trends, Strategies, And Opportunities In The Oncology Biosimilars Market 2021-2030
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Plasma Fractionation Market Global Size, Revenue Growth Development, Business Opportunities, Future
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Intas entra en un acuerdo de licencia exclusivo con Meiji y Dong-A ST para comercializar DMB-3115
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Global Tumor Necrosis Factor Inhibitors Drug Market Top Manufacturers, Latest Innovation with Trends
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
In India, Drugs for COVID Are Being Tested, Approved in Ways That Should Worry Us 25/05/2021
Representative photo: analuisa gamboa/Unsplash
Mumbai: Since the start of the COVID-19 pandemic last year, researchers around the world have evaluated scores of drugs and therapeutic techniques for the disease. Even according to the Clinical Trial Registry of India (CTRI), researchers in the country are testing everything from inhaled camphor and ajwain to Viagra.
This may be desperation, given the brutality of India’s second COVID-19 outbreak. It is also worthwhile in more ways than one to repurpose existing drugs to treat COVID-19.
However, in most cases, a substantial profit motive isn’t too far away. Together with India’s opaque drug regulation apparatus and its propensity to approve substances on little to no evidence – especially during the pandemic itself – these clinical trials warrant a closer look.